Hutrukin to Analyze Safety and PK in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 10, 2023

Primary Completion Date

October 24, 2023

Study Completion Date

April 5, 2024

Conditions
Pharmacokinetics
Interventions
BIOLOGICAL

Hutrukin

Hutrukin that binds the human cytokine IL-1α with high affinity and is an effective blocker of IL-1α biological activity. Hutrukin is a True Human™ therapeutic antibody. That is, the antibody was generated by a natural human immune response and was cloned directly from a human peripheral B lymphocyte. No in vitro affinity maturation or modifications have been made to improve its natural binding affinity. A true human antibody should be effectively non-immunogenic in humans and thus exhibit optimal activity and pharmacokinetics indistinguishable from native IgG1 immunoglobulin.

BIOLOGICAL

Placebo

Placebo control for Hutrukin IV push.

Trial Locations (1)

78759

BioBehavioral Research of Austin, A Telemed2U Company, Austin

All Listed Sponsors
lead

XBiotech, Inc.

INDUSTRY